Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting held earlier , all resolutions were duly passed on a show of hands.
LONDON, UNITED KINGDOM / ACCESSWIRE / June 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that, at the Annual General Meeting (“AGM”) held earlier today, all resolutions were duly passed on a show of hands. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
| Ordinary Resolutions | Votes for | % of votes cast for | Votes Against | % of votes cast against | Total votes cast | Total votes cast as % of ISC (1) | Votes with-held (2) |
| 1. To receive and adopt the Company’s annual accounts for the year ended 31 December 2023. | 172,981,350 | 99.89 | 189,346 | 0.11 | 173,170,696 | 12.91 | 804,255 |
| 2. To approve the Directors’ Remuneration Report which is set out in the 2023 Annual Report and Accounts. | 155,914,909 | 90.14 | 17,056,623 | 9.86 | 172,971,532 | 12.89 | 1,003,419 |
| 3. To re-appoint Sir Marc Feldmann as a Director of the Company. | 168,819,296 | 97.51 | 4,316,573 | 2.49 | 173,135,869 | 12.90 | 839,082 |
| 4. To re-appoint PKF Littlejohn LLP as auditor of the Company to hold office until the conclusion of the next Annual General Meeting of the Company. | 156,805,252 | 99.10 | 1,429,684 | 0.90 | 158,234,936 | 11.79 | 15,740,015 |
| 5. To authorise the Audit Committee to agree the auditor’s remuneration. | 157,329,629 | 90.99 | 15,576,903 | 9.01 | 172,906,532 | 12.89 | 1,068,419 |
| 6. To authorise the Directors to allot shares pursuant to section 551 of the Companies Act 2006. | 153,328,931 | 88.71 | 19,513,766 | 11.29 | 172,842,697 | 12.88 | 1,132,254 |
| Special Resolutions | Votes for | % of votes cast for | Votes against | % of votes cast against | Total votes cast | Total votes cast as % of ISC (1) | Votes with-held (2) |
| 7. To disapply pre-emption rights under section 570 of the Companies Act 2006. | 152,661,902 | 88.30 | 20,235,808 | 11.70 | 172,897,710 | 12.89 | 1,077,241 |
| 8. To approve for calling of general meetings (other than AGMs) on 14 days’ notice. | 172,081,747 | 99.38 | 1,080,015 | 0.62 | 173,161,762 | 12.91 | 813,189 |
(1) The Company’s issued share capital (“ISC”) on 25 June 2024, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 1,341,815,988 ordinary shares.
(2) A ‘vote withheld’ in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.
A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
| Hemogenyx Pharmaceuticals plc | |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
| Peter Redmond, Director | |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Adam Cowl | |
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey, Charles Goodfellow |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on accesswire.com
